Neurocognitive Impairment and Psychiatric Comorbidity in Well-controlled Human Immunodeficiency Virus-infected Thais from the 2NN Cohort Study

Overview

Journal J Neurovirol

Publisher Springer

Specialties Microbiology
Neurology

Date 2010 Jan 8

PMID 20053142

Citations 24

Authors

Wadchara Pumpradit

Jintanat Ananworanich

Sermsak Lolak

Cecilia Shikuma

Robert Paul

Umaporn Siangphoe

Nithima Chaoniti

Peeraporn Kaew-On

Robert Paris

Kiat Ruxrungtham

Victor Valcour

Affiliations

Soon will be listed here.

Abstract

This research is a cross-sectional study to determine the frequency of neurocognitive impairment and psychiatric comorbidity among Thais maintained on highly active antiretroviral therapy (HAART) with undetectable plasma human immunodeficiency virus (HIV) RNA in the 2NN Cohort. Sixty-four subjects were evaluated with neurological examinations, neuropsychological testing, and psychiatric questionnaires. Twenty-four subjects (37.5%) were found to have neurocognitive impairment, with 13 (20.3%), 10 (15.6%), and 1 (1.6%) classified as asymptomatic neurocognitive disorder (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia (HAD), respectively. Three subjects (4.7%) had depression and no cases had significant symptoms of anxiety. A notable proportion of well-controlled individuals exhibited neurocognitive impairment. Anxiety and depression were uncommon.

Citing Articles

Neurocognitive performance and quality of life of older adults with HIV on antiretroviral treatment in Northern Thailand.

Aurpibul L, Sripan P, Tangmunkongvorakul A, Chaikan W, Sarachai S, Srithanaviboonchai K J Int AIDS Soc. 2022; 25 Suppl 4:e25983.

PMID: 36176022 PMC: 9522635. DOI: 10.1002/jia2.25983.

A Meta-Analytic Review of the Effect of Antiretroviral Therapy on Neurocognitive Outcomes in Adults Living with HIV-1 in Low-and Middle-Income Countries.

Michael H, Youbi E, Ohadoma S, Ramlall S, Oosthuizen F, Polyakova M Neuropsychol Rev. 2021; 32(4):828-854.

PMID: 34757490 DOI: 10.1007/s11065-021-09527-y.

Psychometric utility of the international HIV dementia scale and Montreal Cognitive Assessment in HIV-associated asymptomatic neurocognitive impairment.

Aita S, Kaewpoowat Q, Yasri S, Rerkasem A, Rerkasem K, Choovuthayakorn J J Neurovirol. 2021; 27(4):568-578.

PMID: 34185242 DOI: 10.1007/s13365-021-00991-z.

Comparative analysis of human microglial models for studies of HIV replication and pathogenesis.

Rai M, Hammonds J, Pujato M, Mayhew C, Roskin K, Spearman P Retrovirology. 2020; 17(1):35.

PMID: 33213476 PMC: 7678224. DOI: 10.1186/s12977-020-00544-y.

The Impact of Antiretroviral Therapy on Neurocognitive Outcomes Among People Living with HIV in Low- and Middle-Income Countries (LMICs): A Systematic Review.

Michael H, Naidoo S, Mensah K, Ramlall S, Oosthuizen F AIDS Behav. 2020; 25(2):492-523.

PMID: 32851562 DOI: 10.1007/s10461-020-03008-8.

References

Sacktor N, Nakasujja N, Skolasky R, Rezapour M, Robertson K, Musisi S . HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis. 2009; 49(5):780-6. PMC: 2941149. DOI: 10.1086/605284. View

Sacktor N, Nakasujja N, Robertson K, Clifford D . HIV-associated cognitive impairment in sub-Saharan Africa--the potential effect of clade diversity. Nat Clin Pract Neurol. 2007; 3(8):436-43. DOI: 10.1038/ncpneuro0559. View

Wright E, Brew B, Arayawichanont A, Robertson K, Samintharapanya K, Kongsaengdao S . Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology. 2008; 71(1):50-6. DOI: 10.1212/01.wnl.0000316390.17248.65. View

Sacktor N, McDermott M, Marder K, Schifitto G, Selnes O, McArthur J . HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002; 8(2):136-42. DOI: 10.1080/13550280290049615. View

Robertson K, Smurzynski M, Parsons T, Wu K, Bosch R, Wu J . The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007; 21(14):1915-21. DOI: 10.1097/QAD.0b013e32828e4e27. View

Lotrakul M, Sumrithe S, Saipanish R . Reliability and validity of the Thai version of the PHQ-9. BMC Psychiatry. 2008; 8:46. PMC: 2443128. DOI: 10.1186/1471-244X-8-46. View

Ranga U, Shankarappa R, Siddappa N, Ramakrishna L, Nagendran R, Mahalingam M . Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol. 2004; 78(5):2586-90. PMC: 369202. DOI: 10.1128/jvi.78.5.2586-2590.2004. View

Brechtl J, Breitbart W, Galietta M, Krivo S, Rosenfeld B . The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes. J Pain Symptom Manage. 2001; 21(1):41-51. DOI: 10.1016/s0885-3924(00)00245-1. View

van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B . Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004; 363(9417):1253-63. DOI: 10.1016/S0140-6736(04)15997-7. View

10.

Roc A, Ances B, Chawla S, Korczykowski M, Wolf R, Kolson D . Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy. Arch Neurol. 2007; 64(9):1249-57. DOI: 10.1001/archneur.64.9.noc60125. View

11.

Ammassari A, Antinori A, Aloisi M, Trotta M, Murri R, Bartoli L . Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004; 45(5):394-402. DOI: 10.1176/appi.psy.45.5.394. View

12.

Carey C, Woods S, Gonzalez R, Conover E, Marcotte T, Grant I . Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004; 26(3):307-19. DOI: 10.1080/13803390490510031. View

13.

Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, Corpolongo A . Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005; 11(3):265-73. DOI: 10.1080/13550280590952790. View

14.

Judd F, Komiti A, Chua P, Mijch A, Hoy J, Grech P . Nature of depression in patients with HIV/AIDS. Aust N Z J Psychiatry. 2005; 39(9):826-32. DOI: 10.1080/j.1440-1614.2005.01659.x. View

15.

Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori M, Visco-Comandini U . Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007; 45(2):174-82. DOI: 10.1097/QAI.0b013e318042e1ee. View

16.

Antinori A, Arendt G, Becker J, Brew B, Byrd D, Cherner M . Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007; 69(18):1789-99. PMC: 4472366. DOI: 10.1212/01.WNL.0000287431.88658.8b. View

17.

Valcour V, Shiramizu B, Sithinamsuwan P, Nidhinandana S, Ratto-Kim S, Ananworanich J . HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology. 2009; 72(11):992-8. PMC: 2677463. DOI: 10.1212/01.wnl.0000344404.12759.83. View

18.

Liner 2nd K, Hall C, Robertson K . Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease. J Neurovirol. 2007; 13(4):291-304. DOI: 10.1080/13550280701422383. View

19.

Lotrakul M, Sukanich P . Development of the Thai Depression Inventory. J Med Assoc Thai. 2000; 82(12):1200-7. View

20.

Gupta J, Satishchandra P, Gopukumar K, Wilkie F, Waldrop-Valverde D, Ellis R . Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India. J Neurovirol. 2007; 13(3):195-202. DOI: 10.1080/13550280701258407. View